However, considering that class I PI3Ks are present in all cell types, with p110–δ and –γ enriched in leukocytes and B-CLL [59, 74], we can bona fide conclude that PI3K-δ is present in HG3 cells, as confirmed by the observation that the treatment with CAL-101(Idelasib) resulted in a strong reduction of Akt phosphorylated on the activating residue Ser473 (Figure 5C). The gene discussed is AKT1; the disease is B-cell chronic lymphocytic leukemia.